Previous Close | 1.9400 |
Open | 1.9600 |
Bid | 1.5900 x 1300 |
Ask | 1.8900 x 1200 |
Day's Range | 1.8000 - 1.9800 |
52 Week Range | 1.1400 - 2.5900 |
Volume | |
Avg. Volume | 159,601 |
Market Cap | 104.736M |
Beta (5Y Monthly) | 1.65 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.7800 |
Earnings Date | Aug 02, 2022 - Aug 08, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for OTIC
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the H.C. Wainwright Global Investment Conference (Hybrid Conference). A pre-recorded company presentation by the Otonomy management team will be available on the conference website beginning at 7 a.m. ET / 4 a.m. PT on May 24, 2022. A link to the presentation will also become available a
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of preclinical data for OTO-825 at the upcoming American Society of Gene & Cell Therapy (ASGCT) Meeting being held May 16-19 in Washington, DC. Dr. Phillip Uribe from Otonomy will be making a podium presentation entitled “Preclinical Development of an AAV-based Gene Therapy (OTO-825) for Con
Joining me on the call from Otonomy are Dr. David Weber, president and chief executive officer; and Paul Cayer, chief financial and business officer. Before I turn the call over to Dr. Weber, I would like to remind you that today's call will include forward-looking statements based on current expectations.